Anavex Life Sciences (NASDAQ: AVXL) and Grifols SA, Barcelona (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Anavex Life Sciences and Grifols SA, Barcelona, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences 0 0 2 0 3.00
Grifols SA, Barcelona 0 1 3 0 2.75

Anavex Life Sciences presently has a consensus target price of $14.50, indicating a potential upside of 360.32%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Grifols SA, Barcelona.

Valuation & Earnings

This table compares Anavex Life Sciences and Grifols SA, Barcelona’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences N/A N/A -$14.73 million ($0.33) -9.55
Grifols SA, Barcelona $4.48 billion 3.31 $603.60 million $0.93 23.37

Grifols SA, Barcelona has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.

Dividends

Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Anavex Life Sciences does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.

Risk & Volatility

Anavex Life Sciences has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Grifols SA, Barcelona has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Anavex Life Sciences and Grifols SA, Barcelona’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -70.10% -63.39%
Grifols SA, Barcelona 13.16% 18.08% 6.22%

Institutional & Insider Ownership

23.9% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 22.5% of Grifols SA, Barcelona shares are owned by institutional investors. 11.6% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Grifols SA, Barcelona beats Anavex Life Sciences on 9 of the 14 factors compared between the two stocks.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Grifols SA, Barcelona Company Profile

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.